Crossref
Long-term Survival Advantage for Recurrent Ovarian Cancer Patients Receiving Pegylated Liposomal Doxorubicin
European Oncology & Haematology · 2005
DOI: 10.17925/eoh.2005.0.0.83 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Oncology & Haematology, 2005. Verfasst von Alan N Gordon. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Gordon, A. N. (2005). Long-term Survival Advantage for Recurrent Ovarian Cancer Patients Receiving Pegylated Liposomal Doxorubicin. European Oncology & Haematology. https://doi.org/10.17925/eoh.2005.0.0.83
Vancouver
Gordon AN. Long-term Survival Advantage for Recurrent Ovarian Cancer Patients Receiving Pegylated Liposomal Doxorubicin. European Oncology & Haematology. 2005. doi:10.17925/eoh.2005.0.0.83
BibTeX
@article{Gordon2005,
author = {Gordon, Alan N},
title = {Long-term Survival Advantage for Recurrent Ovarian Cancer Patients Receiving Pegylated Liposomal Doxorubicin},
journal = {European Oncology & Haematology},
year = {2005},
doi = {10.17925/eoh.2005.0.0.83}
}
EUVIMED